– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease –
– ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects…Read More
You might also be interested in reading AXS, RON and SLP surge after Axie Infinity developers revamp the project’s tokenomics.